Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith E Karp

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2005
Farnesyl transferase inhibition in hematologic malignanciesJudith E Karp
Leukemia & Lymphoma|March 1, 2014
The state of the union on treatment of acute myeloid leukemiaAshkan Emadi, Judith E Karp
Leukemia & Lymphoma|September 13, 2012
CD30 in myeloid malignancies: hitting the bull's-eye with an available dartAshkan Emadi, Judith E Karp
Pharmacogenomics|August 28, 2012
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaAshkan Emadi, Judith E Karp
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicineIvana Gojo, Judith E Karp
Leukemia Research|December 6, 2001
Overcoming drug resistance: targeting more than one siteJudith E Karp, Bijoyesh P Mookerjee
Leukemia Research|March 28, 2006
Exploiting oxidative damage to overcome resistanceJudith E Karp, B Douglas Smith
Cancer Discovery|December 12, 2013
Personalized therapy for acute myeloid leukemiaChristopher S Hourigan, Judith E Karp
Blood|May 24, 2014
Reason for CPXcitement in AMLJoshua F Zeidner, Judith E Karp
Leukemia Research|May 6, 2011
KLFs and ATRA-induced differentiation: new pathways for exploitationJudith E Karp, Feyruz V Rassool
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2005
Farnesyl transferase inhibition in hematologic malignanciesJudith E Karp
Leukemia & Lymphoma|March 1, 2014
The state of the union on treatment of acute myeloid leukemiaAshkan Emadi, Judith E Karp
Leukemia & Lymphoma|September 13, 2012
CD30 in myeloid malignancies: hitting the bull's-eye with an available dartAshkan Emadi, Judith E Karp
Pharmacogenomics|August 28, 2012
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaAshkan Emadi, Judith E Karp
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicineIvana Gojo, Judith E Karp
Leukemia Research|December 6, 2001
Overcoming drug resistance: targeting more than one siteJudith E Karp, Bijoyesh P Mookerjee
Leukemia Research|March 28, 2006
Exploiting oxidative damage to overcome resistanceJudith E Karp, B Douglas Smith
Cancer Discovery|December 12, 2013
Personalized therapy for acute myeloid leukemiaChristopher S Hourigan, Judith E Karp
Blood|May 24, 2014
Reason for CPXcitement in AMLJoshua F Zeidner, Judith E Karp
Leukemia Research|May 6, 2011
KLFs and ATRA-induced differentiation: new pathways for exploitationJudith E Karp, Feyruz V Rassool
Pageof 15